{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:43:24Z","timestamp":1783691004495,"version":"3.55.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09979-4","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T13:02:09Z","timestamp":1728392529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles"],"prefix":"10.1007","volume":"51","author":[{"given":"Samane","family":"Teymouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Pourhajibagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Bahador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"10","key":"9979_CR1","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3390\/antibiotics11101406","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lin Y, Galgano S, Houdijk J, Xie W, Jin Y et al (2022) Recent progress in phage therapy to modulate multidrug-resistant Acinetobacter baumannii, including in human and poultry. Antibiotics 11(10):1406","journal-title":"Antibiotics"},{"key":"9979_CR2","unstructured":"Control, CfD (2018) Prevention. Antibiotic\/antimicrobial resistance (AR\/AMR). Available on: https:\/\/www.cdcgov\/drugresistance\/index. [Last accessed: 2018, 22 Oct]"},{"key":"9979_CR3","doi-asserted-by":"crossref","unstructured":"LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley R, Wooten D (eds) (2018) Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open forum infectious diseases. Oxford University Press US","DOI":"10.1093\/ofid\/ofy064"},{"key":"9979_CR4","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fimmu.2018.01068","volume":"9","author":"A Tagliabue","year":"2018","unstructured":"Tagliabue A, Rappuoli R (2018) Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 9:1068","journal-title":"Front Immunol"},{"issue":"2","key":"9979_CR5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/v14020194","volume":"14","author":"P Wintachai","year":"2022","unstructured":"Wintachai P, Surachat K, Singkhamanan K (2022) Isolation and characterization of a novel autographiviridae phage and its combined effect with tigecycline in controlling multidrug-resistant Acinetobacter baumannii-Associated skin and soft tissue infections. Viruses 14(2):194","journal-title":"Viruses"},{"issue":"2","key":"9979_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrmicro.2017.148","volume":"16","author":"CM Harding","year":"2018","unstructured":"Harding CM, Hennon SW, Feldman MF (2018) Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol 16(2):91\u2013102","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"9979_CR7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1128\/JB.00906-15","volume":"198","author":"BS Weber","year":"2016","unstructured":"Weber BS, Harding CM, Feldman MF (2016) Pathogenic Acinetobacter: from the cell surface to infinity and beyond. J Bacteriol 198(6):880\u2013887","journal-title":"J Bacteriol"},{"key":"9979_CR8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3389\/fmicb.2020.00928","volume":"11","author":"M Muhammad","year":"2020","unstructured":"Muhammad M, Idris A, Fan X, Guo Y, Yu Y, Jin X et al (2020) Beyond risk: bacterial biofilms and their regulating approaches. Front Microbiol 11:928","journal-title":"Front Microbiol"},{"key":"9979_CR9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3389\/fchem.2019.00824","volume":"7","author":"AD Verderosa","year":"2019","unstructured":"Verderosa AD, Totsika M, Fairfull-Smith KE (2019) Bacterial biofilm eradication agents: a current review. Front Chem 7:824","journal-title":"Front Chem"},{"issue":"1","key":"9979_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/sur.2009.022","volume":"11","author":"DM Guerrero","year":"2010","unstructured":"Guerrero DM, Perez F, Conger NG, Solomkin JS, Adams MD, Rather PN et al (2010) Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease. Surg Infect 11(1):49\u201357","journal-title":"Surg Infect"},{"issue":"10","key":"9979_CR11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/pathogens10101310","volume":"10","author":"G Mancuso","year":"2021","unstructured":"Mancuso G, Midiri A, Gerace E, Biondo C (2021) Bacterial antibiotic resistance: the most critical pathogens. Pathogens 10(10):1310","journal-title":"Pathogens"},{"key":"9979_CR12","doi-asserted-by":"crossref","unstructured":"Reina R, Le\u00f3n-Moya C, Garnacho-Montero J (2022) Treatment of Acinetobacter baumannii severe infections. Med Intensiva (English Edition)","DOI":"10.1016\/j.medine.2022.08.007"},{"issue":"1","key":"9979_CR13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","volume":"30","author":"D Wong","year":"2017","unstructured":"Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B (2017) Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev 30(1):409\u2013447","journal-title":"Clin Microbiol Rev"},{"issue":"13","key":"9979_CR14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA et al (2014) Multistate point-prevalence survey of health care\u2013associated infections. N Engl J Med 370(13):1198\u20131208","journal-title":"N Engl J Med"},{"issue":"4","key":"9979_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijantimicag.2016.01.015","volume":"47","author":"SH Lob","year":"2016","unstructured":"Lob SH, Hoban DJ, Sahm DF, Badal RE (2016) Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 47(4):317\u2013323","journal-title":"Int J Antimicrob Agents"},{"key":"9979_CR16","doi-asserted-by":"crossref","first-page":"100672","DOI":"10.1016\/j.mgene.2020.100672","volume":"24","author":"SS Khazaal","year":"2020","unstructured":"Khazaal SS, Al-Saryi N, Ibrahim SA (2020) Immunomodulation by Acinetobacter baumannii of endotracheal tube biofilm in ventilator-associated pneumonia. Meta Gene 24:100672","journal-title":"Meta Gene"},{"issue":"5","key":"9979_CR17","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s11033-020-05389-4","volume":"47","author":"B Chakravarty","year":"2020","unstructured":"Chakravarty B (2020) Genetic mechanisms of antibiotic resistance and virulence in Acinetobacter baumannii: background, challenges and future prospects. Mol Biol Rep 47(5):4037\u20134046","journal-title":"Mol Biol Rep"},{"issue":"11","key":"9979_CR18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/microorganisms7110556","volume":"7","author":"L Blasco","year":"2019","unstructured":"Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastoy R et al (2019) Combined use of the Ab105-2\u03c6\u2206CI lytic mutant phage and different antibiotics in clinical isolates of multi-resistant Acinetobacter baumannii. Microorganisms 7(11):556","journal-title":"Microorganisms"},{"key":"9979_CR19","doi-asserted-by":"crossref","unstructured":"Nabi-Afjadi M, Teymouri S, Monfared FN, Varnosfaderani SMN, Halimi H (2023) The Human Gut Phageome: Identification and Roles in the Diseases","DOI":"10.33696\/Signaling.4.100"},{"issue":"3","key":"9979_CR20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41579-019-0311-5","volume":"18","author":"MB Dion","year":"2020","unstructured":"Dion MB, Oechslin F, Moineau S (2020) Phage diversity, genomics and phylogeny. Nat Rev Microbiol 18(3):125\u2013138","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"9979_CR21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/bact.1.2.15845","volume":"1","author":"ST Abedon","year":"2011","unstructured":"Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage 1(2):66\u201385","journal-title":"Bacteriophage"},{"issue":"2","key":"9979_CR22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1099\/mic.0.054866-0","volume":"158","author":"MJ Hossain","year":"2012","unstructured":"Hossain MJ, Rahman KS, Terhune JS, Liles MR (2012) An outer membrane porin protein modulates phage susceptibility in Edwardsiella ictaluri. Microbiology 158(2):474\u2013487","journal-title":"Microbiology"},{"issue":"1","key":"9979_CR23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/v15010196","volume":"15","author":"A Leprince","year":"2023","unstructured":"Leprince A, Mahillon J (2023) Phage adsorption to gram-positive bacteria. Viruses 15(1):196","journal-title":"Viruses"},{"issue":"3","key":"9979_CR24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.33073\/pjm-2010-023","volume":"59","author":"D Rakhuba","year":"2010","unstructured":"Rakhuba D, Kolomiets E, Dey ES, Novik G (2010) Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol 59(3):145","journal-title":"Pol J Microbiol"},{"key":"9979_CR25","doi-asserted-by":"crossref","first-page":"1358909","DOI":"10.3389\/fmicb.2024.1358909","volume":"15","author":"LJ Ostenfeld","year":"2024","unstructured":"Ostenfeld LJ, S\u00f8rensen AN, Neve H, Vitt A, Klumpp J, S\u00f8rensen MCH (2024) A hybrid receptor binding protein enables phage F341 infection of Campylobacter by binding to flagella and lipooligosaccharides. Front Microbiol 15:1358909","journal-title":"Front Microbiol"},{"issue":"1","key":"9979_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/bioengineering10010035","volume":"10","author":"Y Tan","year":"2022","unstructured":"Tan Y, Su J, Fu M, Zhang H, Zeng H (2022) Recent advances in phage-based therapeutics for Multi-drug Resistant Acinetobacter baumannii. Bioengineering 10(1):35","journal-title":"Bioengineering"},{"key":"9979_CR27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ et al (2007) Comparative review of the carbapenems. Drugs 67:1027\u20131052","journal-title":"Drugs"},{"key":"9979_CR28","doi-asserted-by":"crossref","unstructured":"Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS (eds) (2019) Antimicrobial susceptibility of Acinetobacter calcoaceticus\u2013Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997\u20132016). Oxford University Press US. Open forum infectious diseases","DOI":"10.1093\/ofid\/ofy293"},{"issue":"8","key":"9979_CR29","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/AAC.01581-07","volume":"52","author":"ES Moland","year":"2008","unstructured":"Moland ES, Craft DW, Hong S-g, Kim S-y, Hachmeister L, Sayed SD et al (2008) In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 52(8):2940\u20132942","journal-title":"Antimicrob Agents Chemother"},{"key":"9979_CR30","doi-asserted-by":"crossref","unstructured":"Navidifar T, Amin M, Rashno M (2019) Effects of sub-inhibitory concentrations of meropenem and tigecycline on the expression of genes regulating pili, efflux pumps and virulence factors involved in biofilm formation by Acinetobacter baumannii. Infect Drug Resist. 1099\u20131111","DOI":"10.2147\/IDR.S199993"},{"issue":"6","key":"9979_CR31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jinf.2020.10.016","volume":"81","author":"P Gallagher","year":"2020","unstructured":"Gallagher P, Baker S (2020) Developing new therapeutic approaches for treating infections caused by multi-drug resistant Acinetobacter baumannii: Acinetobacter baumannii therapeutics. J Infect 81(6):857\u2013861","journal-title":"J Infect"},{"key":"9979_CR32","doi-asserted-by":"crossref","unstructured":"Gedefie A, Demsis W, Ashagrie M, Kassa Y, Tesfaye M, Tilahun M et al (2021) Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infect Drug Resist. 3711\u20133719","DOI":"10.2147\/IDR.S332051"},{"issue":"4","key":"9979_CR33","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/AAC.37.4.750","volume":"37","author":"H Seifert","year":"1993","unstructured":"Seifert H, Baginski R, Schulze A, Pulverer G (1993) Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 37(4):750\u2013753","journal-title":"Antimicrob Agents Chemother"},{"key":"9979_CR34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fmicb.2018.00536","volume":"9","author":"G-S Cho","year":"2018","unstructured":"Cho G-S, Li B, Rostalsky A, Fiedler G, R\u00f6sch N, Igbinosa E et al (2018) Diversity and antibiotic susceptibility of Acinetobacter strains from milk powder produced in Germany. Front Microbiol 9:536","journal-title":"Front Microbiol"},{"issue":"2","key":"9979_CR35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","volume":"73","author":"SC Nang","year":"2021","unstructured":"Nang SC, Azad MA, Velkov T, Zhou QT, Li J (2021) Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev 73(2):679\u2013728","journal-title":"Pharmacol Rev"},{"issue":"3","key":"9979_CR36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/pathogens10030373","volume":"10","author":"I Kyriakidis","year":"2021","unstructured":"Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A (2021) Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 10(3):373","journal-title":"Pathogens"},{"issue":"3","key":"9979_CR37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.diagmicrobio.2008.06.008","volume":"62","author":"L Huang","year":"2008","unstructured":"Huang L, Sun L, Xu G, Xia T (2008) Differential susceptibility to carbapenems due to the AdeABC efflux pump among nosocomial outbreak isolates of Acinetobacter baumannii in a Chinese hospital. Diagn Microbiol Infect Dis 62(3):326\u2013332","journal-title":"Diagn Microbiol Infect Dis"},{"key":"9979_CR38","doi-asserted-by":"crossref","unstructured":"Hawkey J, Ascher DB, Judd LM, Wick RR, Kostoulias X, Cleland H et al (2018) Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection. Microb Genomics. 4(3)","DOI":"10.1099\/mgen.0.000165"},{"issue":"10","key":"9979_CR39","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","volume":"48","author":"S Ibrahim","year":"2021","unstructured":"Ibrahim S, Al-Saryi N, Al-Kadmy IM, Aziz SN (2021) Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep 48(10):6987\u20136998","journal-title":"Mol Biol Rep"},{"issue":"3","key":"9979_CR40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"9979_CR41","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/CCM.0000000000001029","volume":"43","author":"B Spellberg","year":"2015","unstructured":"Spellberg B, Bonomo RA (2015) Combination therapy for extreme drug resistant (XDR) Acinetobacter baumannii: ready for Prime-Time? Crit Care Med 43(6):1332","journal-title":"Crit Care Med"},{"issue":"2","key":"9979_CR42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bcp.13439","volume":"84","author":"RS Hayward","year":"2018","unstructured":"Hayward RS, Harding J, Molloy R, Land L, Longcroft-Neal K, Moore D et al (2018) Adverse effects of a single dose of gentamicin in adults: a systematic review. Br J Clin Pharmacol 84(2):223\u2013238","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"9979_CR43","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","volume":"43","author":"GE Stein","year":"2006","unstructured":"Stein GE, Craig WA (2006) Tigecycline: a critical analysis. Clin Infect Dis 43(4):518\u2013524","journal-title":"Clin Infect Dis"},{"issue":"5","key":"9979_CR44","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3390\/antibiotics12050854","volume":"12","author":"JN van Spijk","year":"2023","unstructured":"van Spijk JN, Beckmann K, Wehrli Eser M, Stirn M, Steuer AE, Saleh L et al (2023) Preliminary Investigation of Side effects of Polymyxin B Administration in Hospitalized horses. Antibiotics 12(5):854","journal-title":"Antibiotics"},{"key":"9979_CR45","first-page":"3","volume":"33","author":"SG As","year":"2019","unstructured":"As SG (2019) CLSI based antibiogram profile and the detection of MDR and XDR strains of Acinetobacter baumannii isolated from urine samples. Med J Islamic Repub Iran 33:3","journal-title":"Med J Islamic Repub Iran"},{"issue":"4","key":"9979_CR46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1089\/mdr.2016.0229","volume":"23","author":"I Goic-Barisic","year":"2017","unstructured":"Goic-Barisic I, Seruga Music M, Kovacic A, Tonkic M, Hrenovic J (2017) Pan drug-resistant environmental isolate of Acinetobacter baumannii from Croatia. Microb Drug Resist 23(4):494\u2013496","journal-title":"Microb Drug Resist"},{"issue":"7","key":"9979_CR47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12033-021-00325-8","volume":"63","author":"F Hemmati","year":"2021","unstructured":"Hemmati F, Rezaee MA, Ebrahimzadeh S, Yousefi L, Nouri R, Kafil HS et al (2021) Novel strategies to combat bacterial biofilms. Mol Biotechnol 63(7):569\u2013586","journal-title":"Mol Biotechnol"},{"key":"9979_CR48","doi-asserted-by":"crossref","unstructured":"Peleg AY (ed) (2007) Editor optimizing therapy for Acinetobacter baumannii. Seminars in respiratory and critical care medicine. \u00a9 Thieme Medical","DOI":"10.1055\/s-2007-996413"},{"key":"9979_CR49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3389\/fphar.2019.00513","volume":"10","author":"N Principi","year":"2019","unstructured":"Principi N, Silvestri E, Esposito S (2019) Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol 10:513","journal-title":"Front Pharmacol"},{"issue":"3","key":"9979_CR50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40259-021-00480-z","volume":"35","author":"M \u0141obocka","year":"2021","unstructured":"\u0141obocka M, D\u0105browska K, G\u00f3rski A (2021) Engineered bacteriophage therapeutics: rationale, challenges and future. BioDrugs 35(3):255\u2013280","journal-title":"BioDrugs"},{"issue":"4","key":"9979_CR51","doi-asserted-by":"crossref","first-page":"e2041","DOI":"10.1002\/rmv.2041","volume":"29","author":"S Rehman","year":"2019","unstructured":"Rehman S, Ali Z, Khan M, Bostan N, Naseem S (2019) The dawn of phage therapy. Rev Med Virol 29(4):e2041","journal-title":"Rev Med Virol"},{"issue":"2","key":"9979_CR52","first-page":"204","volume":"36","author":"FW Twort","year":"1936","unstructured":"Twort FW (1936) Further investigations on the nature of ultra-microscopic viruses and their cultivation. Epidemiol Infect 36(2):204\u2013235","journal-title":"Epidemiol Infect"},{"issue":"1","key":"9979_CR53","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","volume":"6","author":"BK Chan","year":"2016","unstructured":"Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE (2016) Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 6(1):26717","journal-title":"Sci Rep"},{"issue":"1","key":"9979_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1057\/s41599-020-0478-4","volume":"6","author":"C Brives","year":"2020","unstructured":"Brives C, Pourraz J (2020) Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun 6(1):1\u201311","journal-title":"Palgrave Commun"},{"key":"9979_CR55","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3389\/fmicb.2019.00954","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Batra H, Dong J, Chen C, Rao VB, Tao P (2019) Genetic engineering of bacteriophages against infectious diseases. Front Microbiol 10:954","journal-title":"Front Microbiol"},{"key":"9979_CR56","doi-asserted-by":"crossref","first-page":"112836","DOI":"10.1016\/j.lwt.2021.112836","volume":"154","author":"K Shahin","year":"2022","unstructured":"Shahin K, Bao H, Zhu S, Soleimani-Delfan A, He T, Mansoorianfar M et al (2022) Bio-control of O157: H7, and colistin-resistant MCR-1-positive Escherichia coli using a new designed broad host range phage cocktail. LWT 154:112836","journal-title":"LWT"},{"issue":"1","key":"9979_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13567-023-01254-x","volume":"55","author":"P Li","year":"2024","unstructured":"Li P, Guo G, Zheng X, Xu S, Zhou Y, Qin X et al (2024) Therapeutic efficacy of a K5-specific phage and depolymerase against Klebsiella pneumoniae in a mouse model of infection. Vet Res 55(1):1\u201313","journal-title":"Vet Res"},{"key":"9979_CR58","doi-asserted-by":"publisher","unstructured":"Pacios O, Fern\u00e1ndez-Garc\u00eda L, Bleriot I, Blasco L, Gonz\u00e1lez-Bardanca M, L\u00f3pez M et al (2021) Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage vB_KpnM-VAC13 against clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 65(9). https:\/\/doi.org\/10.1128\/aac00900\u2009\u2013\u200921","DOI":"10.1128\/aac"},{"issue":"1","key":"9979_CR59","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1038\/s41598-017-08336-9","volume":"7","author":"JD Van Belleghem","year":"2017","unstructured":"Van Belleghem JD, Clement F, Merabishvili M, Lavigne R, Vaneechoutte M (2017) Pro-and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep 7(1):8004","journal-title":"Sci Rep"},{"issue":"7","key":"9979_CR60","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/v14071493","volume":"14","author":"FH Howard","year":"2022","unstructured":"Howard FH, Kwan A, Winder N, Mughal A, Collado-Rojas C, Muthana M (2022) Understanding immune responses to viruses\u2014do underlying Th1\/Th2 cell biases predict outcome? Viruses 14(7):1493","journal-title":"Viruses"},{"key":"9979_CR61","unstructured":"Janeway CA Jr, Travers P, Walport M, Shlomchik MJ (2001) Principles of innate and adaptive immunity. Immunobiology: The Immune System in Health and Disease 5th edition: Garland Science"},{"key":"9979_CR62","volume-title":"Cellular and Molecular Immunology E-Book: Cellular and Molecular Immunology","author":"AK Abbas","year":"2014","unstructured":"Abbas AK, Lichtman AH, Pillai S (2014) Cellular and Molecular Immunology E-Book: Cellular and Molecular Immunology. Elsevier Health Sciences, E-Book"},{"issue":"6","key":"9979_CR63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tim.2010.03.001","volume":"18","author":"WF Wade","year":"2010","unstructured":"Wade WF, O\u2019Toole GA (2010) Antibodies and immune effectors: shaping Gram-negative bacterial phenotypes. Trends Microbiol 18(6):234\u2013239","journal-title":"Trends Microbiol"},{"issue":"5","key":"9979_CR64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/antibiotics9050268","volume":"9","author":"C Ferriol-Gonz\u00e1lez","year":"2020","unstructured":"Ferriol-Gonz\u00e1lez C, Domingo-Calap P (2020) Phages for biofilm removal. Antibiotics 9(5):268","journal-title":"Antibiotics"},{"key":"9979_CR65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.mib.2017.09.004","volume":"39","author":"DP Pires","year":"2017","unstructured":"Pires DP, Melo LD, Boas DV, Sillankorva S, Azeredo J (2017) Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. Curr Opin Microbiol 39:48\u201356","journal-title":"Curr Opin Microbiol"},{"key":"9979_CR66","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fmed.2020.00426","volume":"7","author":"G Vukotic","year":"2020","unstructured":"Vukotic G, Obradovic M, Novovic K, Di Luca M, Jovcic B, Fira D et al (2020) Characterization, antibiofilm, and depolymerizing activity of two phages active on carbapenem-resistant Acinetobacter baumannii. Front Med 7:426","journal-title":"Front Med"},{"issue":"9","key":"9979_CR67","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.3390\/v13091688","volume":"13","author":"OY Timoshina","year":"2021","unstructured":"Timoshina OY, Shneider MM, Evseev PV, Shchurova AS, Shelenkov AA, Mikhaylova YV et al (2021) Novel Acinetobacter baumannii bacteriophage Aristophanes encoding structural polysaccharide deacetylase. Viruses 13(9):1688","journal-title":"Viruses"},{"key":"9979_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2180-12-1","volume":"12","author":"J Jin","year":"2012","unstructured":"Jin J, Li Z-J, Wang S-W, Wang S-M, Huang D-H, Li Y-H et al (2012) Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol 12:1\u20138","journal-title":"BMC Microbiol"},{"key":"9979_CR69","doi-asserted-by":"crossref","unstructured":"Zhang Y, Shao Y, You H, Shen Y, Miao F, Yuan C et al (2024) Characterization and therapeutic potential of MRABP9, a novel lytic bacteriophage infecting multidrug-resistant Acinetobacter baumannii clinical strains. Virology. 110098","DOI":"10.1016\/j.virol.2024.110098"},{"issue":"1","key":"9979_CR70","doi-asserted-by":"crossref","first-page":"11347","DOI":"10.1038\/s41598-023-38453-7","volume":"13","author":"M Mardiana","year":"2023","unstructured":"Mardiana M, Teh S-H, Tsai Y-C, Yang H-H, Lin L-C, Lin N-T (2023) Characterization of a novel and active temperate phage vB_AbaM_ABMM1 with antibacterial activity against Acinetobacter baumannii infection. Sci Rep 13(1):11347","journal-title":"Sci Rep"},{"issue":"9","key":"9979_CR71","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","volume":"19","author":"S Aslam","year":"2019","unstructured":"Aslam S, Courtwright AM, Koval C, Lehman SM, Morales S, Furr C-LL et al (2019) Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant 19(9):2631\u20132639","journal-title":"Am J Transplant"},{"issue":"1","key":"9979_CR72","doi-asserted-by":"crossref","first-page":"fuab048","DOI":"10.1093\/femsre\/fuab048","volume":"46","author":"JE Egido","year":"2022","unstructured":"Egido JE, Costa AR, Aparicio-Maldonado C, Haas P-J, Brouns SJ (2022) Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiol Rev 46(1):fuab048","journal-title":"FEMS Microbiol Rev"},{"issue":"7","key":"9979_CR73","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/antibiotics11070915","volume":"11","author":"M Hasan","year":"2022","unstructured":"Hasan M, Ahn J (2022) Evolutionary dynamics between phages and bacteria as a possible approach for designing effective phage therapies against antibiotic-resistant bacteria. Antibiotics 11(7):915","journal-title":"Antibiotics"},{"issue":"1","key":"9979_CR74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/antibiotics8010018","volume":"8","author":"A Loureiro","year":"2019","unstructured":"Loureiro A, da Silva GJ (2019) Crispr-cas: converting a bacterial defence mechanism into a state-of-the-art genetic manipulation tool. Antibiotics 8(1):18","journal-title":"Antibiotics"},{"key":"9979_CR75","unstructured":"Harman-McKenna VK (2023) Isolation, Characterization, And Application Of Novel Bacteriophages For Preventing Experimental Infection With Mycobacterium avium subspecies paratuberculosis (MAP) Of Dairy Calves"},{"issue":"2","key":"9979_CR76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41564-020-00830-7","volume":"6","author":"F Gordillo Altamirano","year":"2021","unstructured":"Gordillo Altamirano F, Forsyth JH, Patwa R, Kostoulias X, Trim M, Subedi D et al (2021) Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nat Microbiol 6(2):157\u2013161","journal-title":"Nat Microbiol"},{"issue":"1","key":"9979_CR77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/ijmr.IJMR_2271_18","volume":"154","author":"SR Patel","year":"2021","unstructured":"Patel SR, Pratap CB, Nath G (2021) Evaluation of bacteriophage cocktail on septicaemia caused by colistin-resistant Acinetobacter baumannii in immunocompromised mice model. Indian J Med Res 154(1):141","journal-title":"Indian J Med Res"},{"key":"9979_CR78","doi-asserted-by":"publisher","unstructured":"Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61(10). https:\/\/doi.org\/10.1128\/aac00954\u2009\u2013\u200917","DOI":"10.1128\/aac"},{"issue":"6","key":"9979_CR79","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00284-023-03295-z","volume":"80","author":"Y Li","year":"2023","unstructured":"Li Y, Xiao S, Huang G (2023) Acinetobacter baumannii bacteriophage: progress in isolation, genome sequencing, Preclinical Research, and clinical application. Curr Microbiol 80(6):199","journal-title":"Curr Microbiol"},{"issue":"6","key":"9979_CR80","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/femsre\/fuaa017","volume":"44","author":"DP Pires","year":"2020","unstructured":"Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J (2020) Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev 44(6):684\u2013700","journal-title":"FEMS Microbiol Rev"},{"issue":"4","key":"9979_CR81","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/v11040343","volume":"11","author":"S McCallin","year":"2019","unstructured":"McCallin S, Sacher JC, Zheng J, Chan BK (2019) Current state of compassionate phage therapy. Viruses 11(4):343","journal-title":"Viruses"},{"key":"9979_CR82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4172\/1747-0862.1000050","volume":"6","author":"HM Parracho","year":"2012","unstructured":"Parracho HM, Burrowes BH, Enright MC, McConville ML, Harper DR (2012) The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genetic Medicine: Int J Biomedical Res 6:279","journal-title":"J Mol Genetic Medicine: Int J Biomedical Res"},{"issue":"3","key":"9979_CR83","doi-asserted-by":"crossref","first-page":"e01923","DOI":"10.1128\/aac.01923-21","volume":"66","author":"L Blasco","year":"2022","unstructured":"Blasco L, Bleriot I, Gonz\u00e1lez de Aledo M, Fern\u00e1ndez-Garc\u00eda L, Pacios O, Oliveira H et al (2022) Development of an anti-acinetobacter baumannii biofilm phage cocktail: genomic adaptation to the host. Antimicrob Agents Chemother 66(3):e01923\u2013e01921","journal-title":"Antimicrob Agents Chemother"},{"key":"9979_CR84","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.copbio.2021.02.002","volume":"68","author":"J Azeredo","year":"2021","unstructured":"Azeredo J, Garc\u00eda P, Drulis-Kawa Z (2021) Targeting biofilms using phages and their enzymes. Curr Opin Biotechnol 68:251\u2013261","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"9979_CR85","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/03009734.2019.1688433","volume":"124","author":"AS Nilsson","year":"2019","unstructured":"Nilsson AS (2019) Pharmacological limitations of phage therapy. Ups J Med Sci 124(4):218\u2013227","journal-title":"Ups J Med Sci"},{"issue":"6","key":"9979_CR86","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/fmb.13.47","volume":"8","author":"BK Chan","year":"2013","unstructured":"Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8(6):769\u2013783","journal-title":"Future Microbiol"},{"issue":"10","key":"9979_CR87","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/ph16101347","volume":"16","author":"KM Chung","year":"2023","unstructured":"Chung KM, Nang SC, Tang SS (2023) The Safety of bacteriophages in Treatment of diseases caused by Multidrug-Resistant Bacteria. Pharmaceuticals 16(10):1347","journal-title":"Pharmaceuticals"},{"issue":"1","key":"9979_CR88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/nyas.14533","volume":"1496","author":"OI North","year":"2021","unstructured":"North OI, Brown ED (2021) Phage\u2013antibiotic combinations: a promising approach to constrain resistance evolution in bacteria. Ann N Y Acad Sci 1496(1):23\u201334","journal-title":"Ann N Y Acad Sci"},{"key":"9979_CR89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fcimb.2019.00022","volume":"9","author":"TL Tagliaferri","year":"2019","unstructured":"Tagliaferri TL, Jansen M, Horz H-P (2019) Fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy. Front Cell Infect Microbiol 9:22","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"9979_CR90","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1371\/journal.pone.0000799","volume":"2","author":"AM Comeau","year":"2007","unstructured":"Comeau AM, T\u00e9tart F, Trojet SN, Pr\u00e8re M-F, Krisch H (2007) Phage-antibiotic synergy (PAS): \u03b2-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2(8):e799","journal-title":"PLoS ONE"},{"key":"9979_CR91","doi-asserted-by":"crossref","unstructured":"Altamirano FLG, Kostoulias X, Subedi D, Korneev D, Peleg AY, Barr JJ (2022) Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine. 80","DOI":"10.1016\/j.ebiom.2022.104045"},{"issue":"12","key":"9979_CR92","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.3390\/ijms21124390","volume":"21","author":"B Grygorcewicz","year":"2020","unstructured":"Grygorcewicz B, Roszak M, Golec P, \u015aleboda-Taront D, \u0141ubowska N, G\u00f3rska M et al (2020) Antibiotics act with vB_AbaP_AGC01 phage against Acinetobacter baumannii in human heat-inactivated plasma blood and Galleria mellonella models. Int J Mol Sci 21(12):4390","journal-title":"Int J Mol Sci"},{"key":"9979_CR93","doi-asserted-by":"crossref","first-page":"631585","DOI":"10.3389\/fcimb.2021.631585","volume":"11","author":"X Tan","year":"2021","unstructured":"Tan X, Chen H, Zhang M, Zhao Y, Jiang Y, Liu X et al (2021) Clinical experience of personalized phage therapy against carbapenem-resistant Acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Front Cell Infect Microbiol 11:631585","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"9979_CR94","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/ph16121638","volume":"16","author":"B Zalewska-Pi\u0105tek","year":"2023","unstructured":"Zalewska-Pi\u0105tek B (2023) Phage therapy\u2014challenges, opportunities and future prospects. Pharmaceuticals 16(12):1638","journal-title":"Pharmaceuticals"},{"issue":"7","key":"9979_CR95","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/v10070351","volume":"10","author":"F Oechslin","year":"2018","unstructured":"Oechslin F (2018) Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses 10(7):351","journal-title":"Viruses"},{"issue":"13","key":"9979_CR96","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.7150\/ijbs.60551","volume":"17","author":"X Li","year":"2021","unstructured":"Li X, He Y, Wang Z, Wei J, Hu T, Si J et al (2021) A combination therapy of phages and antibiotics: two is better than one. Int J Biol Sci 17(13):3573","journal-title":"Int J Biol Sci"},{"issue":"5","key":"9979_CR97","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/antibiotics11050570","volume":"11","author":"C Liu","year":"2022","unstructured":"Liu C, Hong Q, Chang RYK, Kwok PCL, Chan H-K (2022) Phage\u2013antibiotic therapy as a promising strategy to combat multidrug-resistant infections and to enhance antimicrobial efficiency. Antibiotics 11(5):570","journal-title":"Antibiotics"},{"issue":"8","key":"9979_CR98","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3390\/antibiotics12081329","volume":"12","author":"A-H Osman","year":"2023","unstructured":"Osman A-H, Kotey FC, Odoom A, Darkwah S, Yeboah RK, Dayie NT et al (2023) The potential of bacteriophage-antibiotic combination therapy in treating infections with multidrug-resistant bacteria. Antibiotics 12(8):1329","journal-title":"Antibiotics"},{"issue":"3","key":"9979_CR99","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/eva.12185","volume":"8","author":"Q Chang","year":"2015","unstructured":"Chang Q, Wang W, Regev-Yochay G, Lipsitch M, Hanage WP (2015) Antibiotics in agriculture and the risk to human health: how worried should we be? Evol Appl 8(3):240\u2013247","journal-title":"Evol Appl"},{"issue":"9","key":"9979_CR100","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/pharmaceutics14091936","volume":"14","author":"M Wdowiak","year":"2022","unstructured":"Wdowiak M, Paczesny J, Raza S (2022) Enhancing the stability of bacteriophages using physical, chemical, and nano-based approaches: a review. Pharmaceutics 14(9):1936","journal-title":"Pharmaceutics"},{"issue":"5","key":"9979_CR101","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/v13050865","volume":"13","author":"H Duyvejonck","year":"2021","unstructured":"Duyvejonck H, Merabishvili M, Vaneechoutte M, De Soir S, Wright R, Friman V-P et al (2021) Evaluation of the stability of bacteriophages in different solutions suitable for the production of magistral preparations in Belgium. Viruses 13(5):865","journal-title":"Viruses"},{"issue":"3","key":"9979_CR102","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jam.15638","volume":"133","author":"D U\u0161jak","year":"2022","unstructured":"U\u0161jak D, Novovi\u0107 K, Filipi\u0107 B, Koji\u0107 M, Filipovi\u0107 N, Stevanovi\u0107 MM et al (2022) In vitro colistin susceptibility of pandrug-resistant Ac. Baumannii is restored in the presence of selenium nanoparticles. J Appl Microbiol 133(3):1197\u20131206","journal-title":"J Appl Microbiol"},{"issue":"1","key":"9979_CR103","doi-asserted-by":"crossref","first-page":"10751","DOI":"10.1038\/s41598-021-90208-4","volume":"11","author":"HF Hetta","year":"2021","unstructured":"Hetta HF, Al-Kadmy IM, Khazaal SS, Abbas S, Suhail A, El-Mokhtar MA et al (2021) Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii. Sci Rep 11(1):10751","journal-title":"Sci Rep"},{"key":"9979_CR104","first-page":"245","volume-title":"Immunological methods","author":"H-W Yu","year":"2015","unstructured":"Yu H-W, Halonen MJ, Pepper IL (2015) Immunological methods. Elsevier, Environmental Microbiology, pp 245\u2013269"},{"issue":"5","key":"9979_CR105","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1039\/C6CS00313C","volume":"46","author":"J Chen","year":"2017","unstructured":"Chen J, Andler SM, Goddard JM, Nugen SR, Rotello VM (2017) Integrating recognition elements with nanomaterials for bacteria sensing. Chem Soc Rev 46(5):1272\u20131283","journal-title":"Chem Soc Rev"},{"issue":"4","key":"9979_CR106","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4103\/0972-9062.328976","volume":"58","author":"M Zandi","year":"2021","unstructured":"Zandi M, Rasooli A, Soltani S, Teymouri S, Mohammadi S, Abbasi S (2021) Biosensor-based methods for Crimean-Congo hemorrhagic fever virus detection. J Vector Borne Dis 58(4):383\u2013385","journal-title":"J Vector Borne Dis"},{"key":"9979_CR107","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jconrel.2022.05.021","volume":"347","author":"T Briot","year":"2022","unstructured":"Briot T, Kolenda C, Ferry T, Medina M, Laurent F, Leboucher G et al (2022) Paving the way for phage therapy using novel drug delivery approaches. J Controlled Release 347:414\u2013424","journal-title":"J Controlled Release"},{"issue":"18","key":"9979_CR108","doi-asserted-by":"crossref","first-page":"115556","DOI":"10.1016\/j.bmc.2020.115556","volume":"28","author":"Z Ka\u017amierczak","year":"2020","unstructured":"Ka\u017amierczak Z, Szostak-Paluch K, Przyby\u0142o M, Langner M, Witkiewicz W, J\u0119druchniewicz N et al (2020) Endocytosis in cellular uptake of drug delivery vectors: molecular aspects in drug development. Bioorg Med Chem 28(18):115556","journal-title":"Bioorg Med Chem"},{"key":"9979_CR109","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3389\/fmicb.2018.02172","volume":"9","author":"S Cinquerrui","year":"2018","unstructured":"Cinquerrui S, Mancuso F, Vladisavljevi\u0107 GT, Bakker SE, Malik DJ (2018) Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing. Front Microbiol 9:2172","journal-title":"Front Microbiol"},{"key":"9979_CR110","doi-asserted-by":"crossref","first-page":"699054","DOI":"10.3389\/fphar.2021.699054","volume":"12","author":"S Kaur","year":"2021","unstructured":"Kaur S, Kumari A, Kumari Negi A, Galav V, Thakur S, Agrawal M et al (2021) Nanotechnology based approaches in phage therapy: overcoming the pharmacological barriers. Front Pharmacol 12:699054","journal-title":"Front Pharmacol"},{"key":"9979_CR111","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jviromet.2016.07.002","volume":"236","author":"S Singla","year":"2016","unstructured":"Singla S, Harjai K, Raza K, Wadhwa S, Katare O, Chhibber S (2016) Phospholipid vesicles encapsulated bacteriophage: a novel approach to enhance phage biodistribution. J Virol Methods 236:68\u201376","journal-title":"J Virol Methods"},{"issue":"4","key":"9979_CR112","doi-asserted-by":"crossref","first-page":"e0153777","DOI":"10.1371\/journal.pone.0153777","volume":"11","author":"S Singla","year":"2016","unstructured":"Singla S, Harjai K, Katare OP, Chhibber S (2016) Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS ONE 11(4):e0153777","journal-title":"PLoS ONE"},{"issue":"7","key":"9979_CR113","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.burns.2017.03.029","volume":"43","author":"P Chadha","year":"2017","unstructured":"Chadha P, Katare OP, Chhibber S (2017) Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns 43(7):1532\u20131543","journal-title":"Burns"},{"key":"9979_CR114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.addr.2016.03.003","volume":"106","author":"M Karimi","year":"2016","unstructured":"Karimi M, Mirshekari H, Basri SMM, Bahrami S, Moghoofei M, Hamblin MR (2016) Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos. Adv Drug Deliv Rev 106:45\u201362","journal-title":"Adv Drug Deliv Rev"},{"key":"9979_CR115","doi-asserted-by":"crossref","first-page":"0004","DOI":"10.34133\/bdr.0004","volume":"5","author":"M Pardo-Freire","year":"2023","unstructured":"Pardo-Freire M, Domingo-Calap P (2023) Phages and nanotechnology: New insights against Multidrug-resistant Bacteria. BioDesign Res 5:0004","journal-title":"BioDesign Res"},{"issue":"2","key":"9979_CR116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.31635\/ccschem.021.202101302","volume":"4","author":"R Qu","year":"2022","unstructured":"Qu R, Zhen X, Jiang X (2022) Emerging designs of aggregation-induced emission agents for enhanced phototherapy applications. CCS Chem 4(2):401\u2013419","journal-title":"CCS Chem"},{"key":"9979_CR117","doi-asserted-by":"crossref","unstructured":"Teymouri S, Pourhajibagher M, Bahador A, Exosomes (2024) Friends or Foes in Microbial Infections? Infectious Disorders Drug Targets","DOI":"10.2174\/0118715265264388231128045954"},{"issue":"3","key":"9979_CR118","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1039\/D0SC04889E","volume":"12","author":"B Ran","year":"2021","unstructured":"Ran B, Yuan Y, Xia W, Li M, Yao Q, Wang Z et al (2021) A photo-sensitizable phage for multidrug-resistant Acinetobacter baumannii therapy and biofilm ablation. Chem Sci 12(3):1054\u20131061","journal-title":"Chem Sci"},{"key":"9979_CR119","doi-asserted-by":"crossref","first-page":"103121","DOI":"10.1016\/j.bioorg.2019.103121","volume":"91","author":"K Ciepluch","year":"2019","unstructured":"Ciepluch K, Maciejewska B, Ga\u0142czy\u0144ska K, Kuc-Ciepluch D, Bryszewska M, Appelhans D et al (2019) The influence of cationic dendrimers on antibacterial activity of phage endolysin against P. aeruginosa cells. Bioorg Chem 91:103121","journal-title":"Bioorg Chem"},{"key":"9979_CR120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1542-5","volume":"21","author":"J Kaur","year":"2020","unstructured":"Kaur J, Kour A, Panda JJ, Harjai K, Chhibber S (2020) Exploring endolysin-loaded alginate-chitosan nanoparticles as future remedy for staphylococcal infections. AAPS PharmSciTech 21:1\u201315","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"9979_CR121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/pharmaceutics14020247","volume":"14","author":"TI Ramos","year":"2022","unstructured":"Ramos TI, Villacis-Aguirre CA, L\u00f3pez-Aguilar KV, Santiago Padilla L, Altamirano C, Toledo JR et al (2022) The Hitchhiker\u2019s guide to human therapeutic nanoparticle development. Pharmaceutics 14(2):247","journal-title":"Pharmaceutics"},{"issue":"4","key":"9979_CR122","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/v10040178","volume":"10","author":"C Rohde","year":"2018","unstructured":"Rohde C, Resch G, Pirnay J-P, Blasdel BG, Debarbieux L, Gelman D et al (2018) Expert opinion on three phage therapy related topics: bacterial phage resistance, phage training and prophages in bacterial production strains. Viruses 10(4):178","journal-title":"Viruses"},{"issue":"1","key":"9979_CR123","doi-asserted-by":"crossref","first-page":"a012518","DOI":"10.1101\/cshperspect.a012518","volume":"4","author":"S Adhya","year":"2014","unstructured":"Adhya S, Merril CR, Biswas B (2014) Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harbor Perspect Med 4(1):a012518","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"9979_CR124","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3389\/fmicb.2020.01161","volume":"11","author":"L Bretaudeau","year":"2020","unstructured":"Bretaudeau L, Tremblais K, Aubrit F, Meichenin M, Arnaud I (2020) Good manufacturing practice (GMP) compliance for phage therapy medicinal products. Front Microbiol 11:1161","journal-title":"Front Microbiol"},{"key":"9979_CR125","doi-asserted-by":"crossref","first-page":"464722","DOI":"10.3389\/fmicb.2019.01674","volume":"10","author":"V Hietala","year":"2019","unstructured":"Hietala V, Horsma-Heikkinen J, Carron A, Skurnik M, Kiljunen S (2019) The removal of endo-and enterotoxins from bacteriophage preparations. Front Microbiol 10:464722","journal-title":"Front Microbiol"},{"issue":"11","key":"9979_CR126","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/cid\/ciz222","volume":"69","author":"R Nir-Paz","year":"2019","unstructured":"Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S et al (2019) Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis 69(11):2015\u20132018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9979_CR127","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/v14010033","volume":"14","author":"S-M Wienhold","year":"2021","unstructured":"Wienhold S-M, Brack MC, Nouailles G, Krishnamoorthy G, Korf IH, Seitz C et al (2021) Preclinical assessment of bacteriophage therapy against experimental Acinetobacter baumannii lung infection. Viruses 14(1):33","journal-title":"Viruses"},{"issue":"6","key":"9979_CR128","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1159\/000486117","volume":"44","author":"S Yin","year":"2018","unstructured":"Yin S, Huang G, Zhang Y, Jiang B, Yang Z, Dong Z et al (2018) Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii. Cell Physiol Biochem 44(6):2337\u20132345","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"9979_CR129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fmb.16.11","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mi Z, Niu W, An X, Yuan X, Liu H et al (2016) Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia. Future Microbiol 11(5):631\u2013641","journal-title":"Future Microbiol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09979-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:30:54Z","timestamp":1738729854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09979-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9979"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09979-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1044"}}